The global Hemoglobinopathies Market is valued at USD 7.70 Billion in 2021 and is expected to reach USD 16.70 Billion by 2028 with a CAGR of 11.7% over the forecast period.
The increasing need for screening for sickle cell disease specifically in newborns is anticipated to drive the growth of the Global Hemoglobinopathies Market.
Scope of Hemoglobinopathies Market Report:
A hemoglobinopathy is an inherited blood disorder in which a person has an abnormal form of hemoglobin or decreased production of hemoglobin. Globally, hemoglobinopathies are one of the most common inherited diseases and much more common in northern and central Europe including Germany due to immigration. A clear understanding of the genetics and structure of the globin chains and Hb is required during the diagnosis of hemoglobinopathies. The most common hemoglobinopathies include sickle cell disease (SCD) and thalassemias (alpha- and beta-). Hemoglobinopathies include a large heterogeneous group of inherited disorders of hemoglobin synthesis that can be subclassified into thalassemia syndromes and structural hemoglobin variants.
Hemoglobinopathies Market report is segmented on the basis of application, diagnosis, end-user, and regional & country level. Based upon application, the hemoglobinopathies market is segmented into thalassemia, sickle cell disease (SCD), and others. Based upon diagnosis, the hemoglobinopathies market is segmented as hemoglobin isoelectric focusing, hemoglobin electrophoresis, high-performance liquid chromatography, genetic testing, and hemoglobin solubility test. On the basis of end-user, the market is divided into hospitals, diagnostic laboratories, and research laboratories.
The regions covered in this Global Hemoglobinopathies Market report are North America, Europe, Asia-Pacific, and the Rest of the World. On the basis of country level, the market of global hemoglobinopathies market is subdivided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Some major key players for Hemoglobinopathies market are,
The hemoglobinopathies market is expected to witness a huge demand immensely from the past few years, mainly due to the increasing cases of sickle cell diseases (SCD), β–thalassemia, and the rising prevalence of blood-related disorders among individuals worldwide. WHO revealed that around 7 % of the world’s population carries a hemoglobinopathy gene. In addition to this, screening and accurate identification of hemoglobin (Hb) variants have become extremely important in the early days to carry out antenatal diagnosis and prevention of Hb disorders by the hemoglobinopathies. According to the world health organization (WHO) reported that nearly 5% of the world population is found with genetic hemoglobin (Hb) disorders and every year more than 42 million carriers and over 12,000 infants’ major and clinically significant hemoglobinopathy. Furthermore, new therapeutic approaches supported by favorable government initiatives from emerging countries are fostering the growth of the global hemoglobinopathies market. However, this approach is specifically required the unidirectional flow, proper training and relatively high cost can turn out to be a restraining factor of this market.
North America is anticipated to dominate the hemoglobinopathies market during the forecast period. Increased immigration of high-risk populations along with the improved treatment and widespread presence of healthcare infrastructure has contributed to the vast implementation of newborn screening programs in this region. Nearly 70,000 to 100,000 Americans have sickle cell disease. The evolvement of non-sickling disorders, such as β thalassemia and Hb H disease varies across the US is largely required the testing solutions like Hemoglobinopathies. In addition, Asia pacific is an exponentially growing region due to the fact that recent advancements in therapeutic approaches attaining huge interest coupled with the rise in awareness of sickle cell diseases in this region.
Report Analysis | Details |
---|---|
Historical data | 2015 - 2020 |
Forecast Period | 2021 - 2028 |
Market Size in 2021: | USD 7.70 Billion |
Base year considered | 2020 |
Forecast Period CAGR %: |
11.7% |
Market Size Expected in 2028: | USD 16.70 Billion |
Tables, Charts & Figures: | 175 |
Pages | 200 |
Hemoglobinopathies Companies | Abbott Diagnostic, Bio-Rad Laboratories Inc., Danaher Corporation, Mindray Medical International Ltd, Nexcelom Bioscience LLC., Nihon Kohden Corporation, PerkinElmer Inc., Siemens Healthineers, Sysmex Corporation others. |
Segments Covered | By Application, By Diagnosis, By End-User |
Regional Analysis | North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa |
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
+44-1173181773
sales@brandessenceresearch.com
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us hr@brandessenceresearch.com
JOIN USFIND ASSISTANCE
LONDON OFFICE
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
FOLLOW US
© Copyright 2025-26 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®